Core Insights - Baxter International reported quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.60 per share, and down from $0.68 per share a year ago, representing an earnings surprise of -1.67% [1] - The company posted revenues of $2.81 billion for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.28%, and down from $3.81 billion year-over-year [2] - Baxter has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.64 on revenues of $2.9 billion, and for the current fiscal year, it is $2.50 on revenues of $11.35 billion [7] - The estimate revisions trend for Baxter was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Products industry, to which Baxter belongs, is currently in the bottom 26% of over 250 Zacks industries, suggesting potential challenges for stock performance [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor sentiment and stock performance [5]

Core Viewpoint - InMode reported quarterly earnings of $0.47 per share, exceeding the Zacks Consensus Estimate of $0.43 per share, and showing an increase from $0.34 per share a year ago, indicating a positive earnings surprise of +9.30% [1][2] Financial Performance - The company achieved revenues of $95.6 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.11%, and up from $86.45 million year-over-year [2] - Over the last four quarters, InMode has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - InMode shares have declined approximately 14.3% since the beginning of the year, contrasting with the S&P 500's gain of 8.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.42 on revenues of $88.4 million, and for the current fiscal year, it is $1.68 on revenues of $365 million [7] Industry Context - The Medical - Products industry, to which InMode belongs, is currently ranked in the bottom 29% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of InMode's stock may be influenced by the overall outlook of the industry [8]